Compare Medtronic PLC (MDT) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Tenet Healthcare Corporation — how do they compare? Medtronic PLC trades at $89.1 (market cap $116.07B), while Tenet Healthcare Corporation trades at $260.99 (market cap $20.89B). The key difference: Medtronic PLC is far larger — about 5.6× Tenet Healthcare Corporation's market cap, and Medtronic PLC pays a 3.18% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| MDT | THC | |
|---|---|---|
Market Cap | $116.07B | $20.89B |
Sector | Health | Health |
52-Week High | $105.35 | $262.63 |
52-Week Low | $73.75 | $161.37 |
Enterprise Value | $134.82B | $31.97B |
Dividend Yield | 3.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.
The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.
Tenet Healthcare (THC) trades at $260.67, up 0.28% today, with strong technical momentum including a golden cross pattern and bullish moving average alignment. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $6.12 versus $4.26 forecast, maintaining a three-quarter earnings beat streak. Valuation metrics remain attractive with P/E of 10.03 and EV/EBITDA of 5.73, while profitability metrics show exceptional ROE of 53.31% and net margin of 9.9%.
The investment outlook remains positive with 81% analyst buy ratings and $281.44 consensus price target representing 8% upside. Key risks include policy headwinds in ACA exchanges and hospital segment challenges, though strong ambulatory growth provides offset. The stock presents a compelling value-growth combination with momentum characteristics, supported by institutional accumulation and positive earnings revisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
